Abstract
Hyperphenylalaninemia (HPA), a disorder of phenylalanine catabolism, is caused primarily by a deficiency of the hepatic phenylalanine-4-hydroxylase (PAH) or by one of the enzymes involved in its cofactor tetrahydrobiopterin (BH4) biosynthesis (GTP cyclohydrolase I (GTPCH) and 6-pyruvoyl-tetrahydropterin synthase (PTPS)) or regeneration (dihydropteridine reductase (DHPR) and pterin carbinolamine-4a-dehydratase (PCD)) (Blau et al. 2001). BH4 is known to be the natural cofactor for PAH, all three isoforms of nitric oxide synthase (NOS), tyrosine-3-hydroxylase, as well as tryptophan-5-hydroxylase (Werner et al. 2011), the latter two being the key enzymes in the biosynthesis of the neurotransmitters dopamine and serotonin. Thus, with two exceptions (see below) any cofactor defect will result in a deficiency of biogenic amines accompanied by HPA. Because phenylalanine is a competitive inhibitor of the uptake of tyrosine and tryptophan and other LNAA across the blood-brain barrier and of the hydroxylases of tyrosine and tryptophan, depletion of catecholamines and serotonin occurs in untreated patients with PAH deficiency. Both groups of HPA (PAH and BH4 deficiency) are heterogeneous disorders varying from severe to mild and benign forms. Because of the different clinical and biochemical severities in this group of diseases, the terms “severe” or “mild” will be used based upon the type of treatment and involvement of the CNS. For the BH4 defects, symptoms may manifest during the first weeks of life, but usually are noted within the first 6 months of life. Birth is generally uneventful, except for an increased incidence of prematurity and lower birth weights in severe PTPS deficiency (Opladen et al. 2012).
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Anjema K, van Rijn M, Hofstede FC, et al (2013) Tetrahydrobiopterin responsiveness in phenylketonuria: prediction with the 48-hour loading test and genotype. Orphanet J Rare Dis 10:103
Belanger-Quintana A, Burlina A, Harding CO, Muntau AC (2011) Up to date knowledge on different treatment strategies for phenylketonuria. Mol Genet Metab 104(Suppl):S19–25
Blau N, Thöny B, Cotton RGH, Hyland K (2001) Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Beaudet al, Sly WS, Valle D, Childs B, Vogelstein B (eds) The metabolic and molecular bases of inherited disease. McGraw-Hill, New York, pp 1725–1776
Blau N, Van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376:1417–1427
Blau N, Hennermann JB, Langenbeck U, Lichter-Konecki U (2011) Diagnosis, classification and genetics of phenylketonuria and tetrahydrobiopterin (BH4) deficiencies. Mol Genet Metab 104:S2–9
Friedman J, Roze E, Abdenur JE et al (2012) Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol 71:520–530
Heintz C, Cotton RG, Blau N (2013) Tetrahydrobiopterin, its mode of action on phenylalanine hydroxylase and importance of genotypes for pharmacological therapy of phenylketonuria. Hum Mutat 34:927–936
Hyland K, Fryburg JS, Wilson WG et al (1997) Oral phenylalanine loading in dopa-responsive dystonia – a possible diagnostic test. Neurology 48:1290–1297
Jäggi L, Zurflüh MR, Schuler A et al (2008) Outcome and long-term follow-up of 36 patients with tetrahydrobiopterin deficiency. Mol Genet Metab 93:295–305
Keil S, Anjema K, van Spronsen FJ et al (2013) Long-term follow-up and outcome of phenylketonuria patients on sapropterin: a retrospective study. Pediatrics 131:e1881–e1888
Levy HB, Burton S, Cederbaum C, Scriver (2007) “Recommendations for evaluation of responsiveness to tetrahydrobiopterin (BH(4)) in phenylketonuria and its use in treatment.” Mol Genet Metab 92(4): 287–291
Opladen T, Okun JG, Burgard P, Blau N, Hoffmann GF (2010) Phenylalanine loading in pediatric patients with dopa-responsive dystonia: revised test protocol and pediatric cut-off values. J Inerit Metab Dis 33:697–703
Opladen T, Hoffmann FG, Blau N (2012) An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inerit Metab Dis 35:963–73
Segawa M (2011) Hereditary progressive dystonia with marked diurnal fluctuation. Brain Dev 33:195–201
van Spronsen FJ, Huijbregts SC, Bosch AM, Leuzzi V (2011) Cognitive, neurophysiological, neurological and psychosocial outcomes in early-treated PKU-patients: a start toward standardized outcome measurement across development. Mol Genet Metab 104(Suppl):S45–51
Werner ER, Blau N, Thöny B (2011) Tetrahydrobiopterin: biochemistry and pathophysiology. Biochem J 438:397–414
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Blau, N., van Spronsen, F.J. (2014). Disorders of Phenylalanine and Tetrahydrobiopterin Metabolism. In: Blau, N., Duran, M., Gibson, K., Dionisi Vici, C. (eds) Physician's Guide to the Diagnosis, Treatment, and Follow-Up of Inherited Metabolic Diseases. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-40337-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-642-40337-8_1
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-40336-1
Online ISBN: 978-3-642-40337-8
eBook Packages: MedicineMedicine (R0)